Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDividends Paid - CommonExchange Rate EffectFree Cash FlowNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Utah Medical Products (UTMD) Share-based Compensation (2016 - 2025)

Utah Medical Products (UTMD) has 16 years of Share-based Compensation data on record, last reported at $94000.0 in Q3 2025.

  • For Q3 2025, Share-based Compensation rose 77.36% year-over-year to $94000.0; the TTM value through Sep 2025 reached $333000.0, up 30.08%, while the annual FY2024 figure was $255000.0, 13.33% up from the prior year.
  • Share-based Compensation reached $94000.0 in Q3 2025 per UTMD's latest filing, up from $86000.0 in the prior quarter.
  • Across five years, Share-based Compensation topped out at $94000.0 in Q3 2025 and bottomed at $38000.0 in Q3 2022.
  • Average Share-based Compensation over 5 years is $57421.1, with a median of $52000.0 recorded in 2024.
  • The widest YoY moves for Share-based Compensation: up 78.26% in 2021, down 16.33% in 2021.
  • A 5-year view of Share-based Compensation shows it stood at $43000.0 in 2021, then skyrocketed by 44.19% to $62000.0 in 2022, then grew by 16.13% to $72000.0 in 2023, then decreased by 1.39% to $71000.0 in 2024, then surged by 32.39% to $94000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Share-based Compensation were $94000.0 in Q3 2025, $86000.0 in Q2 2025, and $82000.0 in Q1 2025.